Adarx Insider Buying Surge Signals Strong Confidence in Post-IPO Growth
Adarx Pharma’s execs buy 1.02 M options, signaling confidence in its siRNA pipeline and Phase 3 data while raising dilution watch for investors.
3 minutes to read
Adarx Pharmaceuticals Inc